We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
Cap. Flow
+$34M
Cap. Flow %
12.86%
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45

Top Buys

Rank Stock Value
1
DTM icon
DT Midstream
DTM
+$1.85M
2
DK icon
Delek US
DK
+$898K
3
SMG icon
ScottsMiracle-Gro
SMG
+$843K
4
VLO icon
Valero Energy
VLO
+$783K
5
FMC icon
FMC
FMC
+$709K

Top Sells

Rank Stock Value
1
COR
Coresite Realty Corporation
COR
+$1.67M
2
XLRN
Acceleron Pharma
XLRN
+$601K
3
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$448K
5
TVTX icon
Travere Therapeutics
TVTX
+$434K

Sector Composition

Rank Sector Weight
1 Real Estate 22.39%
2 Healthcare 18.38%
3 Energy 15.88%
4 Materials 14.07%
5 Utilities 13.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTIL icon
351
Precision BioSciences
DTIL
$178M
$149K 0.06%
669
+59
+10% +$16.5K
VIR icon
352
Vir Biotechnology
VIR
$1.46B
$149K 0.06%
3,568
-1,096
-23% -$42.9K
CVM icon
353
CEL-SCI Corp
CVM
$19.9M
$148K 0.06%
693
+361
+109% +$111K
ALXO icon
354
ALX Oncology
ALXO
$262M
$147K 0.06%
6,844
+3,318
+94% +$143K
CVAC
355
DELISTED
CureVac
CVAC
$146K 0.06%
4,258
+2,108
+98% +$84.8K
PLRX icon
356
Pliant Therapeutics
PLRX
$65M
$146K 0.06%
10,827
+4,361
+67% +$69.3K
NUVB icon
357
Nuvation Bio
NUVB
$2.29B
$144K 0.05%
16,986
-1,654
-9% -$15.2K
HGEN
358
DELISTED
HUMANIGEN, INC.
HGEN
$144K 0.05%
38,740
+28,385
+274% +$166K
KLRS
359
Kalaris Therapeutics
KLRS
$80.9M
$143K 0.05%
482
+75
+18% +$34.8K
ANNX icon
360
Annexon
ANNX
$796M
$139K 0.05%
12,078
+3,035
+34% +$49K
INO icon
361
Inovio Pharmaceuticals
INO
$85.6M
$139K 0.05%
2,316
+328
+16% +$26.3K
NVAX icon
362
Novavax
NVAX
$1.21B
$139K 0.05%
975
-53
-5% -$9.11K
QTTB icon
363
Q32 Bio
QTTB
$435M
$137K 0.05%
2,088
+489
+31% +$47.5K
EVLO
364
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$135K 0.05%
1,113
+462
+71% +$78K
TSHA icon
365
Taysha Gene Therapies
TSHA
$1.61B
$134K 0.05%
11,519
+3,251
+39% +$49K
EWTX icon
366
Edgewise Therapeutics
EWTX
$4.28B
$131K 0.05%
+8,604
New +$155K
ATAI icon
367
AtaiBeckley Inc
ATAI
$2.66B
$125K 0.05%
+16,393
New +$199K
SRNE
368
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$125K 0.05%
26,928
+4,463
+20% +$27.7K
RUBY
369
DELISTED
Rubius Therapeutics, Inc
RUBY
$124K 0.05%
12,773
+5,295
+71% +$73.4K
QURE icon
370
uniQure
QURE
$2.75B
$121K 0.05%
5,841
-246
-4% -$7.05K
CTMX icon
371
CytomX Therapeutics
CTMX
$690M
$118K 0.04%
27,150
-2,208
-8% -$12.9K
HYD icon
372
VanEck High Yield Muni ETF
HYD
$4.44B
$104K 0.04%
1,669
– –
ALDX icon
373
Aldeyra Therapeutics
ALDX
$97.1M
$97K 0.04%
24,298
+7,002
+40% +$53.4K
BTX
374
BlackRock Technology and Private Equity Term Trust
BTX
$895M
$76K 0.03%
5,212
-149
-3% -$2.47K
BBIO icon
375
BridgeBio Pharma
BBIO
$16.4B
$72K 0.03%
4,304
+968
+29% +$41K
13 14
15
16 17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.

By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.

  • Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
  • Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
  • Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
  • Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
  • Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
  • Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
  • Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.